文献速递白血病造血干细胞移植与细胞治疗

双阳性扩增自然杀伤细胞过继免疫治疗复发/难治性急性髓系白血病的概念验证研究

Adoptive immunotherapy with double-bright (CD56bright /CD16bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study.
PubMed 文献 · Br J Haematol · 2021-09-07

该研究在巴西一家学术中心纳入13例高危复发/难治性急性髓系白血病患者,输注来自HLA单倍体相合供者、经K562饲养细胞扩增的双阳性(CD56bright/CD16bright)NK细胞。主要终点为安全性和可行性,次要终点为首次输注后28-30天的总体缓解率和完全缓解率。

要点

  • 高危复发/难治性AML患者接受双阳性扩增NK细胞多次输注未出现剂量限制性毒性。
  • 3例合并中枢神经系统白血病患者出现缓解,其中1例中枢神经系统足菌肿被清除。

核心结论

  • 在高危复发/难治性AML患者中,强化化疗后多次输注扩增并冻存的双阳性NK细胞安全可行,且显示出令人鼓舞的疗效。

研究设计与样本

  • 单中心概念验证研究,纳入13例高危复发/难治性AML患者,NK细胞来自HLA单倍体相合供者,经表达膜结合IL-21的K562饲养细胞扩增。
  • 患者先接受FLAG方案,随后将冻存的NK细胞复苏并输注,每周3次、共6次,分3个剂量组(10^6-10^7 cells/kg/次)。
  • 主要终点为安全性和可行性,次要终点为首次输注后28-30天的总体缓解率和完全缓解率。

主要发现

  • 未观察到剂量限制性毒性、输注相关发热或细胞因子释放综合征。
  • 3例合并中枢神经系统白血病患者出现缓解,并观察到1例中枢神经系统足菌肿被清除。
  • 患者既往中位治疗线数为5线,7例为中危或不良细胞遗传学,3例合并中枢神经系统白血病,1例合并中枢神经系统足菌肿。

临床怎么用

  • 对于高危复发/难治性AML患者,可在强化化疗后考虑多次输注扩增并冻存的双阳性NK细胞,但需在临床研究框架内进行。
  • 治疗前需评估中枢神经系统受累情况,该方案在合并中枢神经系统病变患者中观察到缓解信号。

局限性

  • 为单中心、小样本(13例)的概念验证研究,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with acute myeloid leukaemia (AML) have a five-year survival rate of 28·7%. Natural killer (NK)-cell have anti-leukaemic activity. Here, we report on a series of 13 patients with high-risk R/R AML, treated with repeated infusions of double-bright (CD56bright /CD16bright ) expanded NK cells at an academic centre in Brazil. NK cells from HLA-haploidentical donors were expanded using K562 feeder cells, modified to express membrane-bound interleukin-21. Patients received FLAG, after which cryopreserved NK cells were thawed and infused thrice weekly for six infusions in three dose cohorts (106 -107 cells/kg/infusion). Primary objectives were safety and feasibility. Secondary endpoints included overall response (OR) and complete response (CR) rates at 28-30 days after the first infusion. Patients received a median of five prior lines of therapy, seven with intermediate or adverse cytogenetics, three with concurrent central nervous system (CNS) leukaemia, and one with concurrent CNS mycetoma. No dose-limiting toxicities, infusion-related fever, or cytokine release syndrome were observed. An OR of 78·6% and CR of 50·0% were observed, including responses in three patients with CNS disease and clearance of a CNS mycetoma. Multiple infusions of expanded, cryopreserved NK cells were safely administered after intensive chemotherapy in high-risk patients with R/R AML and demonstrated encouraging outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Silla L, Valim V, Pezzi A, et al. Adoptive immunotherapy with double-bright (CD56bright /CD16bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study. Br J Haematol. 2021. PMID: 34490616. doi:10.1111/bjh.17751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。